NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Appili Therapeutics Inc (TO: APLI)
APLI Technical Analysis
1
As on 27th Aug 2024 APLI STOCK Price closed @ 0.04 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS. |
APLISTOCK Price
Open | 0.04 | Change | Price | % |
High | 0.04 | 1 Day | N/A | N/A |
Low | 0.04 | 1 Week | 0.00 | 0.00 |
Close | 0.04 | 1 Month | 0.00 | 0.00 |
Volume | 14108 | 1 Year | 0.00 | 0.00 |
52 Week High 0.00 | 52 Week Low 0.00 |
TO Canada Most Active Stocks
YRI | 7.89 | 0.13% |
CNQ | 49.67 | % |
MFC | 36.84 | % |
SU | 54.90 | % |
UEX | 0.50 | 16.28% |
BMO | 112.04 | % |
SJR-B | 40.48 | 0.02% |
ENB | 53.36 | % |
VFF | 8.12 | 0.87% |
BNS | 67.22 | % |
TO Canada Top Gainers Stocks
TO Canada Top Losers Stocks
APLI Daily Charts |
APLI Intraday Charts |
Whats New @ Bazaartrend |
APLI Free Analysis |
|
APLI Important Levels Intraday
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
APLI Forecast September 2024
4th UP Forecast | 0 |
3rd UP Forecast | 0 |
2nd UP Forecast | 0 |
1st UP Forecast | 0 |
1st DOWN Forecast | 0 |
2nd DOWN Forecast | 0 |
3rd DOWN Forecast | 0 |
4th DOWN Forecast | 0 |
APLI Weekly Forecast
4th UP Forecast | 0.00 |
3rd UP Forecast | 0.00 |
2nd UP Forecast | 0.00 |
1st UP Forecast | 0.00 |
1st DOWN Forecast | 0.00 |
2nd DOWN Forecast | 0.00 |
3rd DOWN Forecast | 0.00 |
4th DOWN Forecast | 0.00 |
APLI Forecast2024
4th UP Forecast | 0 |
3rd UP Forecast | 0 |
2nd UP Forecast | 0 |
1st UP Forecast | 0 |
1st DOWN Forecast | 0 |
2nd DOWN Forecast | 0 |
3rd DOWN Forecast | 0 |
4th DOWN Forecast | 0 |
Appili Therapeutics Inc ( TO Canada Symbol : APLI )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
APLI Other Details
Segment | EQ | |
Market Capital | 53449572.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
APLI Address
![]() |
APLI Latest News
APLI Business Profile
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada. Address: #21-1344 Summer Street, Halifax, NS, Canada, B3H 0A8
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service